Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1997 Feb;43(2):194-6.
doi: 10.1046/j.1365-2125.1997.54310.x.

The mechanism of cyclosporine toxicity induced by clarithromycin

S T Spicer  1 , C Liddle, J R Chapman, P Barclay, B J Nankivell, P Thomas, P J O'Connell
Affiliations
Clinical Trial

The mechanism of cyclosporine toxicity induced by clarithromycin

S T Spicer et al. Br J Clin Pharmacol. 1997 Feb.

Abstract

Aims: Recently a number of case reports have described the interaction of clarithromycin with cyclosporine A, resulting in cyclosporine toxicity. This interaction is presumed to take place via the hepatic cytochrome P450 enzyme system.

Methods: Following a case of cyclosporine toxicity and acute renal failure in a transplant patient started on clarithromycin, we investigated the effect of oral clarithromycin on the hepatic P450 system in five healthy normal male volunteers, by means of the erythromycin breath test.

Results: Cytochrome P4503A (CYP3A) activity was reduced in all subjects by a mean level of 26% following clarithromycin treatment. This would result in a significant reduction in cyclosporine clearance in patients receiving clarithromycin.

Conclusions: As clarithromycin was shown to inhibit CYP3A activity in all subjects tested, we recommend that a high degree of caution be exercised when clarithromycin is administered to patients receiving cyclosporine therapy or other drugs known to be eliminated by CYP3A-mediated metabolism.

PubMed Disclaimer

MeSH terms